Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Summary

RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of ABX-EGF in treating patients who have prostate cancer that has not responded to hormone therapy.

Timeline

Start

2002-11

Primary completion

2003-09

Completion

2004-02

Drugs

Indications